Retatrutide 'biggest mistakes': what the science supports

What did @christian.fleenor actually say?

The creator argues that fatigue on retatrutide ("R3TA") comes down to three fixable mistakes: eating at too steep a calorie deficit, not drinking enough water or electrolytes, and skimping on sleep. He then pivots to recommending what he calls "mitochondrial peptides" including "Mott's sleep, SLU, PP32, or NAD+" to maximize mitochondria and fat loss.

The lifestyle advice is fairly standard. The peptide stack recommendation is where things get genuinely problematic, and we will get to that. It is also worth noting the video ends with a direct-to-consumer upsell: comment "PROTOCOL" and he will help you personally. That framing warrants scrutiny when someone is recommending compounds by name.

Does the science back this up?

The basic fatigue advice is grounded in real physiology. The peptide claims are not supported by human clinical evidence at the level he implies.

On the lifestyle side: GLP-1 and GLP-1/GIP/GCGR triple agonists like retatrutide reliably suppress appetite, which makes it easy to under-eat. A 2023 trial by Jastreboff et al. in the New England Journal of Medicine showed retatrutide produced significant weight loss, but the trial participants were on structured dietary guidance, not aggressive restriction. Protein intake during GLP-1 use matters: Christoph Taber et al. (2024, Obesity) found higher protein intake during GLP-1 therapy was associated with better lean mass preservation. Electrolyte data is less specific to GLP-1 users, but general exercise physiology supports the claim (Maughan and Shirreffs, 2010, Journal of Sports Sciences). Sleep affecting hormones like cortisol, ghrelin, and insulin sensitivity is well-established (Spiegel et al., 2004, Sleep).

The "mitochondrial peptide" claims are a different story entirely. "Mott's sleep," "SLU," and "PP32" are not recognizable compounds with peer-reviewed human efficacy data for fatigue or fat loss. NAD+ precursors have some early human data (Yoshino et al., 2021, Science) but results are modest and population-specific.

What did they get wrong (or right)?

He got the basics right. Eating too little protein and overall calories on a GLP-1 is a real and documented problem. The clinical term is GLP-1-associated lean mass loss, and it is a legitimate concern that multiple researchers have flagged. Hydration and sleep advice is unremarkable but accurate.

What he got wrong is recommending a stack of compounds, at least one of which is either a trade name or entirely made up, as a solution to drug-related fatigue. Calling NAD+ and unnamed peptides "mitochondrial" tools that will "maximize mitochondria as well as fat loss" is an overclaim not supported by current human trial data. The compounds he names alongside NAD+ do not appear in peer-reviewed literature under those names. Presenting them casually in a TikTok as part of a protocol is misleading to viewers who may not know how thin that evidence base is.

The upsell structure, commenting "PROTOCOL" for personalized help, combined with compound recommendations, raises regulatory flags on a platform reaching people who are actively using a pharmaceutical agent.

What should you actually know?

If you are fatigued on retatrutide or any GLP-1 class drug, start with the boring stuff because it actually works. A 2022 analysis by Wilding et al. in Diabetes, Obesity and Metabolism found that GLP-1 users who maintained higher protein intake and structured resistance training had significantly better body composition outcomes than those who did not. That is not a peptide stack, that is protein and the gym.

On sleep: the evidence that poor sleep degrades insulin sensitivity and increases hunger hormones is strong and replicated. Getting seven to eight hours is not a wellness cliché, it is a metabolic lever.

On the peptide stack: be skeptical of any compound being sold under a name you cannot find in PubMed. NAD+ precursors like NMN and NR have legitimate early research behind them, but the effect sizes in healthy adults are modest. The other compounds named in this video are not verifiable as distinct, studied agents. Do not add unverified compounds to a pharmaceutical regimen without talking to a licensed provider.

Retatrutide is still in clinical development. Phase 2 data is promising, but long-term safety data at the doses being used in non-trial settings is limited. Stacking experimental peptides on top of an already novel compound, based on a TikTok, is not a strategy supported by any clinical guidance.